216 results on '"Sapkal, Gajanan N"'
Search Results
2. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018–2020
3. Infectious causes of acute encephalitis syndrome hospitalizations in Central India, 2018–20
4. Post-campaign coverage evaluation of a measles and rubella supplementary immunization activity in five districts in India, 2019–2020
5. Interferons and Their Role in Viral Infection
6. Childhood encephalitis hospitalizations associated with virus agents in medium-endemic states in India
7. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
8. Intensified Short Symptom Screening Program for Dengue Infection during Pregnancy, India
9. Comparison of two commercial ELISA kits for detection of rubella specific IgM in suspected congenital rubella syndrome cases and rubella IgG antibodies in a serosurvey of pregnant women
10. Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection
11. Sentinel Surveillance for Congenital Rubella Syndrome — India, 2016–2017
12. Effectiveness of Japanese encephalitis SA 14-14-2 live attenuated vaccine among Indian children: Retrospective 1:4 matched case-control study
13. Circulation of a single hepatitis A virus genotype IIIA with two distinct clusters in different states of India
14. Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants
15. Molecular aspects of the teratogenesis of rubella virus
16. Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months
17. First two cases of Monkeypox virus infection in travellers returned from UAE to India, July 2022
18. Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant
19. SARS-CoV-2 seropositivity among non-medical frontline workers in Pune, Maharashtra, India
20. Understanding the dynamics of IgM & IgG antibodies in COVID-19-positive patients
21. Acute Encephalitis with Atypical Presentation of Rubella in Family Cluster, India
22. Cases of SARS-CoV-2 reinfection with Omicron BA.2 post breakthrough infection with Delta and Kappa variants
23. Experiences of sharing results of community based serosurvey with participants in a district of Maharashtra, India
24. Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021
25. Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination
26. Zika a Vector Borne Disease Detected in Newer States of India Amidst the COVID-19 Pandemic
27. Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees
28. Host immune responses in aged rhesus macaques against BBV152, an inactivated SARSCoV-2 vaccine, and crossneutralization with beta and delta variants.
29. Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes
30. Low immune response after 1.5 years of primary SARS-CoV-2 infection and Covishield vaccination lead to SARS-CoV-2 reinfection
31. Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern
32. SARS-CoV-2 Kappa Variant Shows Pathogenicity in a Syrian Hamster Model
33. SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera
34. Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern
35. Detection of Zika virus disease in Thiruvananthapuram, Kerala, India 2021 during the second wave of COVID‐19 pandemic
36. Comparison of neutralizing antibody response in first and second waves of SARS-CoV-2 pandemic in India
37. SARS-CoV-2 Delta derivatives impact on neutralization of Covishield recipient sera
38. Implementing Serosurveys in India: Experiences, Lessons Learned, and Recommendations
39. Coverage of Japanese encephalitis routine vaccination among children in central India.
40. Cases of SARS-CoV-2 reinfection with Omicron BA.2 post breakthrough infection with Delta and Kappa variants.
41. Protective immunity of the primary SARS-CoV-2 infection reduces disease severity post re-infection with Delta variants in Syrian hamsters
42. A case with SARS-CoV-2 reinfection from India
43. Diagnostic Accuracy of Dried Blood Spots Collected on HemaSpot HF Devices Compared to Venous Blood Specimens To Estimate Measles and Rubella Seroprevalence
44. Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals
45. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin
46. Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individuals
47. Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
48. Pathogenic and vaccine strains of Japanese encephalitis virus elicit different levels of human macrophage effector functions
49. Enteroviruses in patients with acute encephalitis, Uttar Pradesh, India
50. Neutralization Potential of Covishield Vaccinated Individuals Sera Against B.1.617.1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.